TapewireFind a company

person · Reporting owner

SMITH IAN F

Disclosed activity across 7 companies

Tapewire entity
16070
SEC CIK
0001197032

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Acorda Therapeutics, Inc.ACOR · Entity 111987DirectorJune 27, 2018June 29, 2018
Foghorn Therapeutics Inc.FHTX · Entity 5820DirectorJune 24, 2026June 25, 2026
INFINITY PHARMACEUTICALS, INC.INFI · Entity 109802DirectorJune 12, 2018June 14, 2018
Odyssey Therapeutics, Inc.ODTX · Entity 4850DirectorMay 07, 2026May 12, 2026
Solid Biosciences Inc.SLDB · Entity 4915DirectorOctober 02, 2026October 06, 2026
Stoke Therapeutics, Inc.STOK · Entity 1723Director · Chief Executive OfficerFebruary 17, 2026February 19, 2026
VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875EVP, COOJune 29, 2018July 03, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Acorda Therapeutics, Inc.

Report date June 27, 2018 · Filed June 29, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $28.15 · Expires 2028-06-27Direct15,000 Reported balance After 2018-06-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2018-06-27 · Grant · Acquired 15,000 · Balance 15,000

F1: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 27, 2018, with the first quarterly installment vesting on September 27, 2018.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 27, 2018, with the first quarterly installment vesting on September 27, 2018.

Foghorn Therapeutics Inc.

Report date June 24, 2026 · Filed June 25, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.08 · Expires 2036-06-23Direct28,000 Reported balance After 2026-06-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-24 · Grant · Acquired 28,000 · Balance 28,000

F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.

INFINITY PHARMACEUTICALS, INC.

Report date June 12, 2018 · Filed June 14, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect45,845 Reported balance After 2018-06-12 transaction · row 1
1 source row

Row 1 · 2018-06-12 · Grant · Acquired 22,857 · Balance 45,845

F1: Pursuant to the issuer's non-employee director compensation program, the reporting person has elected to receive this grant of shares in lieu of cash as payment of such person's $40,000 annual retainer for service as a director.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2028-06-12Direct20,000 Reported balance After 2018-06-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2018-06-12 · Grant · Acquired 20,000 · Balance 20,000

F2: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2028-06-12Direct4,000 Reported balance After 2018-06-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2018-06-12 · Grant · Acquired 4,000 · Balance 4,000

F3: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as Chair of the Audit Committee of the issuer's Board of Directors.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the issuer's non-employee director compensation program, the reporting person has elected to receive this grant of shares in lieu of cash as payment of such person's $40,000 annual retainer for service as a director.

F2: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.

F3: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as Chair of the Audit Committee of the issuer's Board of Directors.

Odyssey Therapeutics, Inc.

Report date May 07, 2026 · Filed May 12, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-05-06Direct27,393 Reported balance After 2026-05-07 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-05-07 · Grant · Acquired 27,393 · Balance 27,393

F1: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.

Solid Biosciences Inc.

Report date October 02, 2026 · Filed October 06, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect141,585 Reported balance After 2026-10-02 transaction · row 1
1 source row

Row 1 · 2026-10-02 · Exercise / conversion · Acquired 3,440 · Balance 141,585

F1: Restricted stock units convert to common stock on a one-for-one basis.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect3,440 Reported balance After 2026-10-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-10-02 · Exercise / conversion · Disposed 3,440 · Balance 3,440

F1: Restricted stock units convert to common stock on a one-for-one basis.

F2: The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units convert to common stock on a one-for-one basis.

F2: The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant.

Stoke Therapeutics, Inc.

Report date February 17, 2026 · Filed February 19, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.09 · Expires 2036-02-16Direct193,000 Reported balance After 2026-02-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-02-17 · Grant · Acquired 193,000 · Balance 193,000

F1: The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2030-02-15Direct129,000 Reported balance After 2026-02-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-02-17 · Grant · Acquired 129,000 · Balance 129,000

F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement.

F3: The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement.

F3: The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date.

VERTEX PHARMACEUTICALS INC / MA

Report date June 29, 2018 · Filed July 03, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect46,699 Ending reported balance After 2018-06-29 transaction · row 3
3 source rows · reconciled sequence

Row 1 · 2018-06-29 · Exercise / conversion · Acquired 23,375 · Balance 70,074

Row 2 · 2018-06-29 · Sale · Disposed 4,741 · Balance 65,333

F1: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $165.22 (range $165.00 to $165.89).

F3: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Row 3 · 2018-06-29 · Sale · Disposed 18,634 · Balance 46,699

F1: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.

F3: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $166.57 (range $166.38 to $166.67).

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $131.89 · Expires 2025-07-20Direct10,625 Reported balance After 2018-06-29 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2018-06-29 · Exercise / conversion · Disposed 23,375 · Balance 10,625

F5: The option vests in 16 quarterly installments from 7/21/2015.

Common StockSEC Table I · non-derivativeIndirect401(k)5,306 Reported balance Holding disclosure · report date 2018-06-29 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 5,306

Filing footnotes · ownership attribution and instrument terms

F1: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $165.22 (range $165.00 to $165.89).

F3: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $166.57 (range $166.38 to $166.67).

F5: The option vests in 16 quarterly installments from 7/21/2015.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 06, 2023 Filed Jun 9, 2023 01:15 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantDirector Stock Option (Right to Buy) · Derivative 9,650 $0.00 Strike: $6.37 $0.00
Disclosure

SEC source: 0000899243-23-014998 · doc4.xml · derivative · entry 3

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,650

Underlying: Common Stock · 9,650 shares

Expires 2033-06-06

F3 · derivative.exercise_date: This option was granted on June 6, 2023 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

Read SEC document
April 03, 2023 Filed Jun 9, 2023 01:15 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 15,569 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-014998 · doc4.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,709

Underlying: Common Stock · 15,569 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the First Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.

F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the First Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.

Read SEC document
April 03, 2023 Filed Jun 9, 2023 01:15 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 15,569 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-23-014998 · doc4.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,239

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
January 03, 2023 Filed Jan 6, 2023 02:46 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantRestricted Stock Units · Derivative 62,278 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-001134 · doc4.xml · derivative · entry 4

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,278

Underlying: Common Stock · 62,278 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "Smith RSUs").

F3 · derivative.exercise_date: The Smith RSUs (as defined in footnote 4) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the First Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full.

F3 · derivative.expiration_date: The Smith RSUs (as defined in footnote 4) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the First Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full.

Read SEC document
January 03, 2023 Filed Jan 6, 2023 02:46 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionStock Option (Right to Buy) · Derivative 70,796 $0.00 Strike: $5.62 $0.00
Disclosure

SEC source: 0000899243-23-001134 · doc4.xml · derivative · entry 3

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,796

Underlying: Common Stock · 70,796 shares

Expires 2033-01-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The Smith RSUs (as defined in footnote 4) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the First Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full.

Read SEC document
January 03, 2023 Filed Jan 6, 2023 02:46 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 1,620 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-001134 · doc4.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,620 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2022 and vested in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant.

F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2022 and vested in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant.

Read SEC document
January 03, 2023 Filed Jan 6, 2023 02:46 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 1,620 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-23-001134 · doc4.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,670

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
December 13, 2022 Filed Dec 15, 2022 23:15 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantDirector Stock Option (Right to Buy) · Derivative 9,650 $0.00 Strike: $6.47 $0.00
Disclosure

SEC source: 0000899243-22-038696 · doc4.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,650

Underlying: Common Stock · 9,650 shares

Expires 2032-12-13

F2 · derivative.exercise_date: This option was granted on December 13, 2022 and vests in full on the one-year anniversary of the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

Read SEC document
December 02, 2022 Filed Dec 5, 2022 23:02 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantCommon Stock 13,172 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-037693 · doc4.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 356,380

F1 · price: The reporting person acquired 13,172 shares of the issuer's common stock pursuant to the issuer's acquisition of all of the outstanding capital stock of AavantiBio, Inc. on December 2, 2022.

Read SEC document
October 03, 2022 Filed Oct 4, 2022 20:50 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 24,312 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-052331 · doc4.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,312

Underlying: Common Stock · 24,312 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2022 and vest in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant, subject to continued service as a director, and in the event of a change in control, the vesting schedule of the award will accelerate in full.

F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2022 and vest in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant, subject to continued service as a director, and in the event of a change in control, the vesting schedule of the award will accelerate in full.

Read SEC document
October 03, 2022 Filed Oct 4, 2022 20:50 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 24,312 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-052331 · doc4.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 343,208

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
July 03, 2022 Filed Jul 6, 2022 20:40 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 24,313 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-041164 · doc4.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,624

Underlying: Common Stock · 24,313 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2022 and vest in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant, subject to continued service as a director, and in the event of a change in control, the vesting schedule of the award will accelerate in full.

F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2022 and vest in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant, subject to continued service as a director, and in the event of a change in control, the vesting schedule of the award will accelerate in full.

Read SEC document
July 03, 2022 Filed Jul 6, 2022 20:40 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 24,313 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-041164 · doc4.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 318,896

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
June 21, 2022 Filed Jun 23, 2022 01:00 UTC Foghorn Therapeutics Inc. FHTX · Entity 5820 GrantStock Options (Right to buy) · Derivative 16,000 $0.00 Strike: $13.81 $0.00
Disclosure

SEC source: 0001562180-22-005317 · primarydocument.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2032-06-20

Read SEC document
June 07, 2022 Filed Jun 9, 2022 21:12 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantDirector Stock Option (Right to Buy) · Derivative 51,000 $0.00 Strike: $0.63 $0.00
Disclosure

SEC source: 0001209191-22-035463 · doc4.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,000

Underlying: Common Stock · 51,000 shares

Expires 2032-06-07

F1 · derivative.exercise_date: This option was granted on June 7, 2022 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

Read SEC document
April 03, 2022 Filed Apr 5, 2022 20:32 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 24,313 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-023040 · doc4.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,937

Underlying: Common Stock · 24,313 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2022 and vest in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant, subject to continued service as a director, and in the event of a change in control, the vesting schedule will accelerate in full.

F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2022 and vest in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant, subject to continued service as a director, and in the event of a change in control, the vesting schedule will accelerate in full.

Read SEC document
April 03, 2022 Filed Apr 5, 2022 20:32 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 24,313 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-023040 · doc4.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 294,583

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
January 03, 2022 Filed Jan 5, 2022 22:22 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantRestricted Stock Units · Derivative 97,250 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-001816 · doc4.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,250

Underlying: Common Stock · 97,250 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuers common stock.

F3 · derivative.exercise_date: The restricted stock units were granted on January 3, 2022 and vest on the same schedule as set forth in footnote (1) above.

F3 · derivative.expiration_date: The restricted stock units were granted on January 3, 2022 and vest on the same schedule as set forth in footnote (1) above.

Read SEC document
January 03, 2022 Filed Jan 5, 2022 22:22 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantDirector Stock Option (Right to Buy) · Derivative 194,500 $0.00 Strike: $1.78 $0.00
Disclosure

SEC source: 0001209191-22-001816 · doc4.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 194,500

Underlying: Common Stock · 194,500 shares

Expires 2032-01-03

F1 · derivative.exercise_date: This option was granted on January 3, 2022 pursuant to a services agreement between the reporting person and the Issuer and will vest in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant, subject to continued service as a director, and in the event of a change in control, the vesting schedule of the option will accelerate in full.

Read SEC document
June 23, 2021 Filed Jun 24, 2021 20:58 UTC Foghorn Therapeutics Inc. FHTX · Entity 5820 GrantStock Options (Right to buy) · Derivative 12,530 $0.00 Strike: $10.24 $0.00
Disclosure

SEC source: 0001562180-21-004483 · primarydocument.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,530

Underlying: Common Stock · 12,530 shares

Expires 2031-06-22

F1 · derivative.exercise_date: The option was granted pursuant to a consulting agreement effective June 23, 2021 (the "Effective Date"). The option will vest as to 1/12 of the underlying shares of common stock on the first day of each month beginning on August 1, 2021, with the balance of then-unvested shares to vest one year after the Effective Date.

Read SEC document
June 16, 2021 Filed Jun 21, 2021 20:00 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantDirector Stock Option (Right to Buy) · Derivative 30,000 $0.00 Strike: $3.94 $0.00
Disclosure

SEC source: 0001209191-21-041938 · doc4.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2031-06-16

F1 · derivative.exercise_date: This option was granted on June 16, 2021 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

Read SEC document
April 27, 2021 Filed Apr 29, 2021 21:01 UTC Foghorn Therapeutics Inc. FHTX · Entity 5820 GrantStock Options (Right to buy) · Derivative 25,060 $11.50 Strike: $11.50 $288,190.00
Disclosure

SEC source: 0001562180-21-003018 · primarydocument.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,060

Underlying: Common Stock · 25,060 shares

Expires 2031-04-26

F1 · derivative.exercise_date: The options will vest as to 25% of the underlying shares of common stock on April 27, 2022, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested.

Read SEC document
January 04, 2021 Filed Jan 6, 2021 21:06 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantStock Option (Right to Buy) · Derivative 389,000 $0.00 Strike: $7.84 $0.00
Disclosure

SEC source: 0001209191-21-001966 · doc4.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 389,000

Underlying: Common Stock · 389,000 shares

Expires 2031-01-04

F1 · derivative.exercise_date: This option was granted on January 4, 2021 and will vest in equal quarterly installments beginning three months from the date of the grant with the final installment vesting date being the later of the completion of a specified service requirement under his consulting agreement or 12 months from the date of the grant, subject to continued service as a director or consultant, and in the event of a change in control, the vesting schedule of the option will accelerate in full.

Read SEC document
December 10, 2020 Filed Dec 14, 2020 21:22 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantCommon Stock 270,270 $3.70 $999,999.00
Disclosure

SEC source: 0001209191-20-063218 · doc4.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 270,270

Read SEC document
June 16, 2020 Filed Jun 18, 2020 20:28 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantDirector Stock Option (Right to Buy) · Derivative 200,000 $0.00 Strike: $3.03 $0.00
Disclosure

SEC source: 0001209191-20-037594 · doc4.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2030-06-16

F1 · derivative.exercise_date: This option was granted on June 16, 2020 and will vest in equal quarterly installments beginning three months from the date of grant and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

Read SEC document
April 15, 2020 Filed Apr 16, 2020 11:28 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantDirector Stock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $2.49 $0.00
Disclosure

SEC source: 0001209191-20-024599 · doc4.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2030-04-15

F1 · derivative.exercise_date: This option was granted on April 15, 2020 and vests as to one-third of the total number of shares on each of the next three anniversaries of the grant date.

Read SEC document
June 29, 2018 Filed Jul 3, 2018 20:25 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionStock Option (Right to Buy) · Derivative 23,375 $0.00 Strike: $131.89 $0.00
Disclosure

SEC source: 0001209191-18-041074 · doc4.xml · derivative · entry 5

SMITH IAN F · CIK 0001197032 · EVP, COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,625

Underlying: Common Stock · 23,375 shares

Expires 2025-07-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 7/21/2015.

Read SEC document
June 29, 2018 Filed Jul 3, 2018 20:25 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 18,634 $166.57 $3,103,865.38
Disclosure

SEC source: 0001209191-18-041074 · doc4.xml · nonDerivative · entry 3

SMITH IAN F · CIK 0001197032 · EVP, COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,699

F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.

F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4 · price: Open market sales reported on this line occurred at a weighted average price of $166.57 (range $166.38 to $166.67).

Read SEC document
June 29, 2018 Filed Jul 3, 2018 20:25 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 4,741 $165.22 $783,308.02
Disclosure

SEC source: 0001209191-18-041074 · doc4.xml · nonDerivative · entry 2

SMITH IAN F · CIK 0001197032 · EVP, COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,333

F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.

F2 · price: Open market sales reported on this line occurred at a weighted average price of $165.22 (range $165.00 to $165.89).

F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Read SEC document
June 29, 2018 Filed Jul 3, 2018 20:25 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionCommon Stock 23,375 $131.89 $3,082,928.75
Disclosure

SEC source: 0001209191-18-041074 · doc4.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · EVP, COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,074

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 27, 2018 Filed Jun 29, 2018 07:52 UTC Acorda Therapeutics, Inc. ACOR · Entity 111987 GrantNon-Employee Stock Option · Derivative 15,000 $0.00 Strike: $28.15 $0.00
Disclosure

SEC source: 0001209191-18-039999 · doc4.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2028-06-27

F1 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 27, 2018, with the first quarterly installment vesting on September 27, 2018.

Read SEC document
June 22, 2018 Filed Jun 26, 2018 21:18 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionStock Option (Right to Buy) · Derivative 4,250 $0.00 Strike: $109.14 $0.00
Disclosure

SEC source: 0001209191-18-039524 · doc4.xml · derivative · entry 4

SMITH IAN F · CIK 0001197032 · EVP, COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,750

Underlying: Common Stock · 4,250 shares

Expires 2025-02-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2015.

Read SEC document
June 22, 2018 Filed Jun 26, 2018 21:18 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 4,250 $160.00 $680,000.00
Disclosure

SEC source: 0001209191-18-039524 · doc4.xml · nonDerivative · entry 2

SMITH IAN F · CIK 0001197032 · EVP, COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,699

F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.

Read SEC document
June 22, 2018 Filed Jun 26, 2018 21:18 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionCommon Stock 4,250 $109.14 $463,845.00
Disclosure

SEC source: 0001209191-18-039524 · doc4.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · EVP, COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,949

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 15, 2018 Filed Jun 19, 2018 16:19 UTC Acorda Therapeutics, Inc. ACOR · Entity 111987 Exercise / conversionNon-Employee Stock Option · Derivative 15,000 $0.00 Strike: $13.80 $0.00
Disclosure

SEC source: 0001209191-18-038543 · doc4.xml · derivative · entry 5

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2027-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Exercises and sales pursuant to a 10b5-1 plan.

F4 · derivative.exercise_date: The shares subject to these options vested in installments and were fully vested on 5/31/2018.

Read SEC document
June 15, 2018 Filed Jun 19, 2018 16:19 UTC Acorda Therapeutics, Inc. ACOR · Entity 111987 Exercise / conversionNon-Employee Stock Option · Derivative 10,000 $0.00 Strike: $25.45 $0.00
Disclosure

SEC source: 0001209191-18-038543 · doc4.xml · derivative · entry 4

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2019-06-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Exercises and sales pursuant to a 10b5-1 plan.

F3 · derivative.exercise_date: The shares subject to these options vested in installments and were fully vested on 6/22/2010.

Read SEC document
June 15, 2018 Filed Jun 19, 2018 16:19 UTC Acorda Therapeutics, Inc. ACOR · Entity 111987 SaleCommon Stock 25,000 $31.42 $785,567.50
Disclosure

SEC source: 0001209191-18-038543 · doc4.xml · nonDerivative · entry 3

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Exercises and sales pursuant to a 10b5-1 plan.

F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $31.15 to $31.55 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
June 15, 2018 Filed Jun 19, 2018 16:19 UTC Acorda Therapeutics, Inc. ACOR · Entity 111987 Exercise / conversionCommon Stock 15,000 $13.80 $207,000.00
Disclosure

SEC source: 0001209191-18-038543 · doc4.xml · nonDerivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Exercises and sales pursuant to a 10b5-1 plan.

Read SEC document
June 15, 2018 Filed Jun 19, 2018 16:19 UTC Acorda Therapeutics, Inc. ACOR · Entity 111987 Exercise / conversionCommon Stock 10,000 $25.45 $254,500.00
Disclosure

SEC source: 0001209191-18-038543 · doc4.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Exercises and sales pursuant to a 10b5-1 plan.

Read SEC document
June 12, 2018 Filed Jun 14, 2018 08:34 UTC INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 GrantStock Option (right to buy) · Derivative 4,000 $0.00 Strike: $1.75 $0.00
Disclosure

SEC source: 0000899243-18-016532 · doc4.xml · derivative · entry 3

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,000

Underlying: Common Stock · 4,000 shares

Expires 2028-06-12

F3 · derivative.exercise_date: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as Chair of the Audit Committee of the issuer's Board of Directors.

Read SEC document
June 12, 2018 Filed Jun 14, 2018 08:34 UTC INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 GrantStock Option (right to buy) · Derivative 20,000 $0.00 Strike: $1.75 $0.00
Disclosure

SEC source: 0000899243-18-016532 · doc4.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2028-06-12

F2 · derivative.exercise_date: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.

Read SEC document
June 12, 2018 Filed Jun 14, 2018 08:34 UTC INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 GrantCommon Stock 22,857 $1.75 $39,999.75
Disclosure

SEC source: 0000899243-18-016532 · doc4.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,845

F1 · shares: Pursuant to the issuer's non-employee director compensation program, the reporting person has elected to receive this grant of shares in lieu of cash as payment of such person's $40,000 annual retainer for service as a director.

Read SEC document
May 15, 2018 Filed May 16, 2018 21:21 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 217 $155.78 $33,804.26
Disclosure

SEC source: 0001209191-18-030604 · doc4.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · EVP, COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,699

F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.

Read SEC document
May 11, 2018 Filed May 15, 2018 20:21 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionStock Option (Right to Buy) · Derivative 1,941 $0.00 Strike: $86.52 $0.00
Disclosure

SEC source: 0001209191-18-030207 · doc4.xml · derivative · entry 6

SMITH IAN F · CIK 0001197032 · EVP, COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,358

Underlying: Common Stock · 1,941 shares

Expires 2027-02-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/3/2017.

Read SEC document
May 11, 2018 Filed May 15, 2018 20:21 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionStock Option (Right to Buy) · Derivative 2,155 $0.00 Strike: $91.05 $0.00
Disclosure

SEC source: 0001209191-18-030207 · doc4.xml · derivative · entry 5

SMITH IAN F · CIK 0001197032 · EVP, COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,086

Underlying: Common Stock · 2,155 shares

Expires 2026-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/2/2016.

Read SEC document
May 11, 2018 Filed May 15, 2018 20:21 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 4,096 $155.00 $634,880.00
Disclosure

SEC source: 0001209191-18-030207 · doc4.xml · nonDerivative · entry 3

SMITH IAN F · CIK 0001197032 · EVP, COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,699

F1 · kind: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.

Read SEC document
May 11, 2018 Filed May 15, 2018 20:21 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionCommon Stock 1,941 $86.52 $167,935.32
Disclosure

SEC source: 0001209191-18-030207 · doc4.xml · nonDerivative · entry 2

SMITH IAN F · CIK 0001197032 · EVP, COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,795

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 11, 2018 Filed May 15, 2018 20:21 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionCommon Stock 2,155 $91.05 $196,212.75
Disclosure

SEC source: 0001209191-18-030207 · doc4.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · EVP, COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,854

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 02, 2018 Filed May 4, 2018 17:50 UTC Acorda Therapeutics, Inc. ACOR · Entity 111987 Exercise / conversionNon-Employee Stock Option · Derivative 10,000 $0.00 Strike: $20.16 $0.00
Disclosure

SEC source: 0001209191-18-028179 · doc4.xml · derivative · entry 4

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2018-05-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2018 on the expiration date reported within Table II unless exercised.

F4 · derivative.exercise_date: The shares subject to these options vested in installments and were fully vested on 05/21/2009.

Read SEC document
May 02, 2018 Filed May 4, 2018 17:50 UTC Acorda Therapeutics, Inc. ACOR · Entity 111987 SaleCommon Stock 6,323 $23.86 $150,897.13
Disclosure

SEC source: 0001209191-18-028179 · doc4.xml · nonDerivative · entry 3

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2018 on the expiration date reported within Table II unless exercised.

F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $23.7750 to $24.0500 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.